etoposide has been researched along with lutetium lu 177 dotatate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akhurst, T; Cullinane, C; Eu, P; Hicks, RJ; Lewin, J; Mileshkin, L; Rao, A; Waldeck, K; Watkins, DN | 1 |
| Halfdanarson, TR; Leventakos, K; Molina, JR; Uprety, D | 1 |
1 review(s) available for etoposide and lutetium lu 177 dotatate
| Article | Year |
|---|---|
Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Capecitabine; Carcinoid Tumor; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Everolimus; Humans; Immune Checkpoint Inhibitors; Lung Neoplasms; Lymph Node Excision; Molecular Targeted Therapy; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pneumonectomy; Protein Kinase Inhibitors; Radiopharmaceuticals; Receptors, Somatostatin; Somatostatin; Temozolomide; Watchful Waiting | 2020 |
1 other study(ies) available for etoposide and lutetium lu 177 dotatate
| Article | Year |
|---|---|
Peptide receptor chemoradionuclide therapy in small cell carcinoma: from bench to bedside.
Topics: Animals; Antineoplastic Agents; Carboplatin; Carcinoma, Small Cell; Cell Line, Tumor; Etoposide; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Octreotide; Organometallic Compounds; Radiopharmaceuticals; Receptors, Somatostatin; Small Cell Lung Carcinoma; Translational Research, Biomedical | 2015 |